DE60336307D1 - Camp-reguliertes phosphoprotein für die diagnose und behandlung von neurodegenerativen krankheiten - Google Patents

Camp-reguliertes phosphoprotein für die diagnose und behandlung von neurodegenerativen krankheiten

Info

Publication number
DE60336307D1
DE60336307D1 DE60336307T DE60336307T DE60336307D1 DE 60336307 D1 DE60336307 D1 DE 60336307D1 DE 60336307 T DE60336307 T DE 60336307T DE 60336307 T DE60336307 T DE 60336307T DE 60336307 D1 DE60336307 D1 DE 60336307D1
Authority
DE
Germany
Prior art keywords
disease
htarpp
alzheimer
camp
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336307T
Other languages
English (en)
Inventor
Rainer Hipfel
Jozef Hanes
Der Kammer Heinz Von
Johannes Pohlner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Application granted granted Critical
Publication of DE60336307D1 publication Critical patent/DE60336307D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60336307T 2002-04-02 2003-04-01 Camp-reguliertes phosphoprotein für die diagnose und behandlung von neurodegenerativen krankheiten Expired - Lifetime DE60336307D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36897002P 2002-04-02 2002-04-02
EP02007522 2002-04-02
PCT/EP2003/003364 WO2003083482A1 (en) 2002-04-02 2003-04-01 Camp-regulated phosphoprotein for diagnostic and therapeutic use in neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DE60336307D1 true DE60336307D1 (de) 2011-04-21

Family

ID=43646220

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336307T Expired - Lifetime DE60336307D1 (de) 2002-04-02 2003-04-01 Camp-reguliertes phosphoprotein für die diagnose und behandlung von neurodegenerativen krankheiten

Country Status (6)

Country Link
US (1) US20060024305A1 (de)
EP (1) EP1490694B1 (de)
AT (1) ATE501437T1 (de)
AU (1) AU2003229586A1 (de)
DE (1) DE60336307D1 (de)
WO (1) WO2003083482A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5777195A (en) * 1996-05-17 1998-07-07 The Rockefeller University Knockout mutant mouse for DARPP-32 and use thereof
AR031361A1 (es) * 2001-04-26 2003-09-24 Ruben Juan Sferco Instrumento para la realizacion de colangiografia operatoria

Also Published As

Publication number Publication date
EP1490694A1 (de) 2004-12-29
EP1490694B1 (de) 2011-03-09
AU2003229586A1 (en) 2003-10-13
ATE501437T1 (de) 2011-03-15
US20060024305A1 (en) 2006-02-02
WO2003083482A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
ATE495269T1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
ATE501437T1 (de) Camp-reguliertes phosphoprotein für die diagnose und behandlung von neurodegenerativen krankheiten
DE60235996D1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
ATE458834T1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
WO2003087403A3 (en) Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases
DE60227650D1 (de) Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer-krankheit und relatierte neurodegeneratiefe störungen
ATE534751T1 (de) Verwendung von prkx zur diagnose und therapie von alzheimer krankheit
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
WO2003100092A3 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
WO2003085131A3 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
WO2003104811A3 (en) DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES
WO2004020665A3 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
WO2004035823A3 (en) Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1490694

Country of ref document: EP

Representative=s name: VON KREISLER SELTING WERNER, DE